Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML
Public ClinicalTrials.gov record NCT00123474. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Two-by-Two, Multicenter, Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects With Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic Myelogenous Leukemia Who Are Resistant or Intolerant to Imatinib Mesylate (Gleevec)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase III study of BMS-354825 in subjects with chronic phase Philadelphia chromosome or BCR-ABL positive chronic myelogenous leukemia, who are resistant or intolerant to imatinib mesylate (Gleevec).
Study identification
- NCT ID
- NCT00123474
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 724 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2005 (Type not available)
- Primary completion
- Sep 2006 (Actual)
- Completion
- Jul 2014 (Actual)
- Last update posted
- Aug 25, 2016
2005 – 2014
United States locations
- U.S. sites
- 40
- U.S. states
- 24
- U.S. cities
- 36
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University Of Alabama At Birmingham | Birmingham | Alabama | 35294 | — |
| Central Hematology Oncology Medical Group Inc. | Alhambra | California | 91801 | — |
| Pacific Cancer Medical Center Inc | Anaheim | California | 92801 | — |
| Loma Linda University Cancer Center | Loma Linda | California | 92354 | — |
| Pacific Shores Medical Group | Long Beach | California | 90813 | — |
| Ucla Dept. Of Medicine | Los Angeles | California | 90095 | — |
| Ventura County Hematology-Oncology Specialists | Oxnard | California | 93030 | — |
| Kaiser Permanente Medical Center | Vallejo | California | 94589 | — |
| Georgetown University Med Ctr | Washington D.C. | District of Columbia | 20007 | — |
| Washington Cancer Institute At Washington Hospital Center | Washington D.C. | District of Columbia | 20010 | — |
| University Of Florida | Gainesville | Florida | 32610 | — |
| University Of Miami | Miami | Florida | 33136 | — |
| Md Anderson Cancer Center Orlando | Orlando | Florida | 32806 | — |
| Emory University School Of Medicine | Atlanta | Georgia | 30322 | — |
| Georgia Cancer Specialists | Atlanta | Georgia | 30341 | — |
| Gwinnett Hospital System Inc. | Lawrenceville | Georgia | 30046 | — |
| Northwestern University Feinberg School Of Medicine | Chicago | Illinois | 60611 | — |
| University Of Chicago | Chicago | Illinois | 60637 | — |
| Oncology Hematology Associates Of Central Illinois, Pc | Peoria | Illinois | 61615 | — |
| Indiana University Cancer Center | Indianapolis | Indiana | 46202 | — |
| University Of Kansas Medical Center | Westwood | Kansas | 66205 | — |
| University Of Kentucky | Lexington | Kentucky | 40536 | — |
| University Of Maryland | Baltimore | Maryland | 21201 | — |
| Dana Faber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Washington University School Of Medicine | St Louis | Missouri | 63110 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Devetten, Marcel | Omaha | Nebraska | 68198 | — |
| Nevada Cancer Institute | Las Vegas | Nevada | 89135 | — |
| The Cancer Center At Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| The Cancer Institute Of New Jersey | New Brunswick | New Jersey | 08903 | — |
| New York Presbyterian Hospital | New York | New York | 10021 | — |
| University Of North Carolina At Chapel Hill | Chapel Hill | North Carolina | 27599 | — |
| Cleveland Clinic Foundation | Cleveland | Ohio | 44195 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Western Pennsylvania Cancer Institute | Pittsburgh | Pennsylvania | 15224 | — |
| Sarah Cannon Research Institute | Nashville | Tennessee | 37203 | — |
| Ut Southwestern Medical Center | Dallas | Texas | 75390 | — |
| The University Of Texas Md Anderson Cancer Center | Houston | Texas | 77030 | — |
| Seattle Cancer Care Alliance | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 97 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00123474, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 25, 2016 · Synced Oct 31, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00123474 live on ClinicalTrials.gov.